Denali Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DNLI and other ETFs, options, and stocks.

About DNLI

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. 

CEO
Ryan J. Watts
CEORyan J. Watts
Employees
503
Employees503
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
2013
Founded2013
Employees
503
Employees503

DNLI Key Statistics

Market cap
3.65B
Market cap3.65B
Price-Earnings ratio
-7.86
Price-Earnings ratio-7.86
Dividend yield
Dividend yield
Average volume
1.94M
Average volume1.94M
High today
$23.05
High today$23.05
Low today
$22.01
Low today$22.01
Open price
$22.50
Open price$22.50
Volume
1.84M
Volume1.84M
52 Week high
$27.30
52 Week high$27.30
52 Week low
$12.58
52 Week low$12.58

Stock Snapshot

As of today, Denali Therapeutics(DNLI) shares are valued at $23.02. The company's market cap stands at 3.65B, with a P/E ratio of -7.86.

During the trading session on 2026-07-15, Denali Therapeutics(DNLI) shares reached a daily high of $23.05 and a low of $22.01. At a current price of $23.02, the stock is +4.6% higher than the low and still -0.1% under the high.

Trading activity shows a volume of 1.84M, compared to an average daily volume of 1.94M.

The stock's 52-week range extends from a low of $12.58 to a high of $27.30.

The stock's 52-week range extends from a low of $12.58 to a high of $27.30.

DNLI News

Investing.com 3d
JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating - Investing.com

...

JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating - Investing.com
Simply Wall St 6d
T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics

T. Rowe Price Investment Management disclosed in a recent Schedule 13G/A filing that it owns about 10.2% of Denali Therapeutics’ outstanding shares, with sole v...

T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics

Analyst ratings

95%

of 19 ratings
Buy
94.7%
Hold
5.3%
Sell
0%

People also own

Based on the portfolios of people who own DNLI. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.